Interleukin-1β Gene (IL-1B) rs16944 (-511 C > T) Promoter Polymorphism Is Associated with Cutaneous Melanoma Susceptibility, Stage, and Anatomical Localization in a Northern Italian Case–Control Study
Current Oncology · 2026
DOI: 10.3390/curroncol33070436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Sabina Cauci und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Udine, Piazzale Kolbe 4, 33100 Udine, Italy. Hauptthemen laut MEDLINE: Melanoma, Interleukin-1beta, Skin Neoplasms, Promoter Regions, Genetic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Udine.
Abstract (Originalsprache)
Immunity plays critical roles in cutaneous melanoma. We investigated the association between the pro-inflammatory interleukin-1β gene (IL-1B) rs16944 (-511 C > T) promoter single nucleotide polymorphism (SNP) and cutaneous melanoma susceptibility and clinical features. This observational case–control study included 133 patients with cutaneous melanoma and 900 healthy controls from Northeastern Italy. The rs16944 C > T polymorphism was determined by genomic DNA restriction fragment analysis. The IL-1B rs16944 C allele (OR = 1.44, p = 0.014) and CC genotype (OR = 1.48, p = 0.037) were associated with modestly higher odds of melanoma. Among melanoma patients, the CC genotype was associated with Stage I disease (OR = 2.45, p = 0.016) and Breslow thickness ≤ 0.75 mm (OR = 2.27, p = 0.049), whereas it was less frequent in Stage IV melanoma (OR = 0.37, p = 0.029). The CT genotype was associated with Stage IV melanoma (OR = 3.03, p = 0.014) and with lower-limb (OR = 2.45, p = 0.038) and lower-extremity (OR = 3.09, p = 0.005) melanoma. These divergent associations are exploratory and do not establish disease trajectory or a functional effect of rs16944; mechanistic interpretation remains uncertain because IL-1β expression or activity was not measured in this cohort. To our knowledge, this is the first report of an association between a genetic polymorphism and lower-limb/lower-extremity melanoma. These exploratory findings require confirmation in independent cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Udine, Piazzale Kolbe 4, 33100 Udine, Italy.
- Institute of Dermatology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Santa Maria della Misericordia, Friuli Centrale University Healthcare Hospital of Udine, 33100 Udine, Italy.
- Fondazione Italiana Fegato ETS-Italian Liver Foundation ETS, 34149 Trieste, Italy.
ORCID-Profile: Giuseppe Stinco
Förderung
- University of Udine
Zitieren
APA
Cauci, S., Buligan, C., Nacci, P., Petris, G., & Stinco, G. (2026). Interleukin-1β Gene (IL-1B) rs16944 (-511 C > T) Promoter Polymorphism Is Associated with Cutaneous Melanoma Susceptibility, Stage, and Anatomical Localization in a Northern Italian Case–Control Study. Current Oncology. https://doi.org/10.3390/curroncol33070436
Vancouver
Cauci S, Buligan C, Nacci P, Petris G, Stinco G. Interleukin-1β Gene (IL-1B) rs16944 (-511 C > T) Promoter Polymorphism Is Associated with Cutaneous Melanoma Susceptibility, Stage, and Anatomical Localization in a Northern Italian Case–Control Study. Current Oncology. 2026. doi:10.3390/curroncol33070436
BibTeX
@article{Cauci2026,
author = {Cauci, Sabina and Buligan, Cinzia and Nacci, Patrizia and Petris, Gianluca and Stinco, Giuseppe},
title = {Interleukin-1β Gene (IL-1B) rs16944 (-511 C > T) Promoter Polymorphism Is Associated with Cutaneous Melanoma Susceptibility, Stage, and Anatomical Localization in a Northern Italian Case–Control Study},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33070436}
}
EUVIMED